Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2018 16:15 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Schedules Fiscal First Quarter 2019 Financial Results Conference Call and Webcast

Call scheduled for Tuesday, August 14 at 10:30am Eastern Time. NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage medical device and biopharmaceutical...
July 30, 2018 08:30 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Announces Start of Manufacturing of Ventilator Compatible NO Generator and Delivery System

FDA 510(k) submission expected in the first quarter of calendar 2019 Sparton's Watertown facility to provide manufacturing services GARDEN CITY, N.Y. and REHOVOT, Israel, July 30, 2018 (GLOBE...
July 16, 2018 08:30 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Announces Human and In-Vitro Nitric Oxide (NO) Data Presented at the 3rd Annual World Bronchiectasis Conference

Presentations highlighted the direct killing effect of NO on Mycobacterium abscessus (M. abscessus) and Pseudomonas aeruginosa (P. aeruginosa) as well as the use of the NO generator and delivery...
June 27, 2018 16:30 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Announces Human and In-Vitro Nitric Oxide Data to be Presented at the 3rd Annual World Bronchiectasis Conference

Two presentations to highlight the direct killing effect of nitric oxide and the use of the nitric oxide generator and delivery system as a potential therapy for Mycobacterium abscessus complex...
June 14, 2018 08:00 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Reports Financial Results for Three Months Ended March 31, 2018

Announced positive top-line data for Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study Presented data from its inhaled Nitric Oxide study in patients infected with mycobacterium abscessus complex...
June 13, 2018 16:30 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Reports Positive Top Line Results from its Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study in Infants

Pivotal study expected to commence in the fourth quarter of calendar year 2019 NEW YORK, June 13, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and...
June 07, 2018 16:17 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Announces Change to Fiscal Year End and Financial Results Conference Call and Webcast for the Three Months Ended March 31, 2018

Call scheduled for Thursday, June 14, 2018 at 8:30am Eastern Time NEW YORK, June 07, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on...
May 30, 2018 16:30 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the...
May 23, 2018 08:30 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Presented Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex (MABSC) at the 2018 American Thoracic Society Conference

Incremental data presented on eradication of MABSC and Pseudomonas aeruginosa NEW YORK, May 23, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and...
May 15, 2018 16:30 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics to Present Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex at the 2018 American Thoracic Society Conference

NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the...